Parkinson's Disease Dementia and Potential Therapeutic Strategies
暂无分享,去创建一个
C. Adler | J. Caviness | L. Lue | D. Walker
[1] M. Ruegg,et al. Neuropathology in Mice Expressing Mouse Alpha-Synuclein , 2011, PloS one.
[2] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[3] S. Sando,et al. Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. , 2010, Parkinsonism & related disorders.
[4] D. Dickson,et al. Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation , 2010, Neurodegenerative Diseases.
[5] J. Hindle,et al. Ageing, neurodegeneration and Parkinson's disease. , 2010, Age and ageing.
[6] G. Pezzoli,et al. Levodopa in Parkinson's disease: from the past to the future , 2010, Expert opinion on pharmacotherapy.
[7] Uwe Walter,et al. Transcranial sonography findings related to non-motor features of Parkinson's disease , 2010, Journal of the Neurological Sciences.
[8] R. Inzelberg,et al. Are genetic and sporadic Parkinson's disease patients equally susceptible to develop dementia? , 2010, Journal of the Neurological Sciences.
[9] Xiongwei Zhu,et al. Amyloid-β-Derived Diffusible Ligands Cause Impaired Axonal Transport of Mitochondria in Neurons , 2010, Neurodegenerative Diseases.
[10] H. Benamer,et al. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: A systematic review , 2010, Movement disorders : official journal of the Movement Disorder Society.
[11] M. Otto,et al. Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure , 2010, Journal of Neural Transmission.
[12] N. Cairns,et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia , 2010, Neurology.
[13] G. Halliday,et al. The progression of pathology in Parkinson's disease , 2010, Annals of the New York Academy of Sciences.
[14] Thomas Wisniewski,et al. Vaccination as a therapeutic approach to Alzheimer's disease. , 2010, The Mount Sinai journal of medicine, New York.
[15] K. Fountas,et al. Genetic basis of Parkinson disease. , 2010, Neurosurgical focus.
[16] D. Dickson,et al. Evidence in favor of Braak staging of Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[17] William Dauer,et al. The biology and pathology of the familial Parkinson's disease protein LRRK2 , 2010, Movement disorders : official journal of the Movement Disorder Society.
[18] D. Sulzer. Clues to how alpha‐synuclein damages neurons in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[19] G. Cuny. Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. , 2009, Current pharmaceutical design.
[20] J. H. Boo,et al. The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start? , 2009, Advanced drug delivery reviews.
[21] A. Siderowf,et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease , 2009, Neurology.
[22] Vasanti S. Anand,et al. LRRK2 in Parkinson’s disease: biochemical functions , 2009, The FEBS journal.
[23] P. Webber,et al. LRRK2 in Parkinson’s disease: function in cells and neurodegeneration , 2009, The FEBS journal.
[24] W. Klein,et al. Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. , 2009, Toxicology and applied pharmacology.
[25] H. Qing,et al. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. , 2009, Biochemical and biophysical research communications.
[26] J. Cooper,et al. Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson’s disease pathogenesis , 2009, Journal of neurochemistry.
[27] M. Sierks,et al. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells , 2009, Neuroscience Letters.
[28] K. Jellinger. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. , 2009, Biochimica et biophysica acta.
[29] E. Londos,et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial , 2009, The Lancet Neurology.
[30] M. Mena,et al. Half a century of L-DOPA. , 2009, Current topics in medicinal chemistry.
[31] T. Montine,et al. Cognitive impairment and dementia in patients with Parkinson disease. , 2009, Current topics in medicinal chemistry.
[32] Jaime Kulisevsky,et al. Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment , 2009, Movement disorders : official journal of the Movement Disorder Society.
[33] H. Shill,et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.
[34] C. Richter-Landsberg,et al. α-Synuclein Aggregation and Ser-129 Phosphorylation-dependent Cell Death in Oligodendroglial Cells* , 2009, Journal of Biological Chemistry.
[35] D. Aarsland,et al. APOE Alleles in Parkinson Disease and Their Relationship to Cognitive Decline: A Population-based, Longitudinal Study , 2009, Journal of geriatric psychiatry and neurology.
[36] A. Goris,et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease , 2009, Journal of Neurology.
[37] P. Steinacker,et al. Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review , 2009, CNS neuroscience & therapeutics.
[38] A. Bush,et al. Targeting the Progression of Parkinson’s Disease , 2009, Current neuropharmacology.
[39] Daniel Weintraub,et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. , 2009, Parkinsonism & related disorders.
[40] Gianmario Sambuceti,et al. Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study , 2009, Movement disorders : official journal of the Movement Disorder Society.
[41] Daniel Weintraub,et al. Montreal Cognitive Assessment Performance in Patients with Parkinson's Disease with “Normal” Global Cognition According to Mini‐Mental State Examination Score , 2009, Journal of the American Geriatrics Society.
[42] M. Onofrj,et al. Peripheral cytokines profile in Parkinson’s disease , 2009, Brain, Behavior, and Immunity.
[43] Normand L. Frigon,et al. Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System*S⃞ , 2009, Journal of Biological Chemistry.
[44] T. Foroud,et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset , 2009, Neurology.
[45] David J Brooks,et al. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography , 2009, Movement disorders : official journal of the Movement Disorder Society.
[46] Nick C Fox,et al. Serial volumetric MRI in Parkinsonian disorders , 2009, Movement disorders : official journal of the Movement Disorder Society.
[47] E. Tolosa,et al. MRI and cognitive impairment in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[48] E. Tolosa,et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s disease , 2008, Neuroscience Letters.
[49] A. Ariza,et al. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. , 2008, Current medicinal chemistry.
[50] A. Brice,et al. α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.
[51] W Poewe,et al. Diagnosis and management of Parkinson's disease dementia , 2008, International journal of clinical practice.
[52] V. Uversky. Alpha-synuclein misfolding and neurodegenerative diseases. , 2008, Current protein & peptide science.
[53] D. Brooks. The role of structural and functional imaging in parkinsonian states with a description of PET technology. , 2008, Seminars in neurology.
[54] Y. Itoyama,et al. Serine 129 Phosphorylation of α-Synuclein Induces Unfolded Protein Response-mediated Cell Death* , 2008, Journal of Biological Chemistry.
[55] Winnie S. Liang,et al. Neuronal gene expression correlates of Parkinson's disease with dementia , 2008, Movement disorders : official journal of the Movement Disorder Society.
[56] Jaime Kulisevsky,et al. Parkinson's disease‐cognitive rating scale: A new cognitive scale specific for Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[57] E. Waxman,et al. Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008, Journal of neuropathology and experimental neurology.
[58] Keith A. Johnson,et al. Imaging amyloid deposition in Lewy body diseases , 2008, Neurology.
[59] V. Dhawan,et al. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease , 2008, Neurology.
[60] G. Schellenberg,et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. , 2008, Archives of neurology.
[61] M. Onofrj,et al. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. , 2008, Brain : a journal of neurology.
[62] D. Weintraub,et al. Parkinson's disease--Part 3: Neuropsychiatric symptoms. , 2008, The American journal of managed care.
[63] N. Hattori,et al. CLINICOPATHOLOGIC STUDY OF A SNCA GENE DUPLICATION PATIENT WITH PARKINSON DISEASE AND DEMENTIA , 2008, Neurology.
[64] B. Jeon,et al. α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.
[65] W. Klein,et al. Why Alzheimer’s is a disease of memory: The attack on synapses by Aß oligomers (ADDLs) , 2008, The journal of nutrition, health & aging.
[66] N. Srivastava,et al. Functional Restoration Using Basic Fibroblast Growth Factor (bFGF) Infusion in Kainic Acid Induced Cognitive Dysfunction in Rat: Neurobehavioural and Neurochemical Studies , 2008, Neurochemical Research.
[67] M. Oda,et al. Auditory event-related potentials in Parkinson's disease: prominent correlation with attention. , 2007, Parkinsonism & related disorders.
[68] E. Tolosa,et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[69] Armin Giese,et al. Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding , 2007, The Journal of Neuroscience.
[70] I. Sokal,et al. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.
[71] C. Adler,et al. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. , 2007, Parkinsonism & related disorders.
[72] H. Shill,et al. Defining mild cognitive impairment in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[73] R. Bullock,et al. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. , 2007, Current Alzheimer research.
[74] D J Brooks,et al. DLB and PDD boundary issues , 2007, Neurology.
[75] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[76] D. Aarsland,et al. A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[77] W. Poewe,et al. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.
[78] D. Brooks,et al. Amyloid deposition and glucose metabolism in Parkinson's disease dementia (PDD): An [C-11]PIB and [F-18]FDG PET study , 2007 .
[79] P. Mcgeer,et al. The Role of Anti-Inflammatory Agents in Parkinson’s Disease , 2007, CNS drugs.
[80] Stephanie B. Conant,et al. Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study , 2006, Journal of Neuroinflammation.
[81] C. Rowe,et al. II.P13 Amyloid load in Parkinson's Disease Dementia (PDD) and Lewy Body Dementia (LBD) measured with 11C-PIB PET , 2006 .
[82] W. Weiner,et al. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.
[83] Xuemei Huang,et al. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. , 2006, Archives of neurology.
[84] P. Brown. Clinical neurophysiology of myoclonus , 2006 .
[85] M. Sawada,et al. Role of cytokines in inflammatory process in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.
[86] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[87] S Minoshima,et al. Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.
[88] I. McKeith,et al. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging , 2005, Movement disorders : official journal of the Movement Disorder Society.
[89] G. Levy. Dementia in Parkinson's disease challenges the “gold standard” , 2005, Annals of neurology.
[90] D. Aarsland,et al. A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[91] M. Danhof,et al. Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.
[92] Makoto Hashimoto,et al. Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.
[93] H. Braak,et al. Cognitive status correlates with neuropathologic stage in Parkinson disease , 2005, Neurology.
[94] John R. Adams,et al. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. , 2005, Brain research. Molecular brain research.
[95] C. Summerfield,et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. , 2005, Archives of neurology.
[96] Ultrastructure of the serotoninergic system of the motor region of the cerebral cortex , 1991, Neuroscience and Behavioral Physiology.
[97] E. Masliah,et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.
[98] P. Hobson,et al. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom , 2004, Movement disorders : official journal of the Movement Disorder Society.
[99] I. McKeith,et al. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. , 2004, Brain : a journal of neurology.
[100] P. Newhouse,et al. Effects of nicotinic stimulation on cognitive performance. , 2004, Current opinion in pharmacology.
[101] C. Lyketsos,et al. Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease , 2004, International journal of geriatric psychiatry.
[102] Nick C Fox,et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study , 2003, The Lancet.
[103] I. McKeith,et al. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[104] Murat Emre,et al. What causes mental dysfunction in Parkinson's disease? , 2003, Movement disorders : official journal of the Movement Disorder Society.
[105] A. Lees,et al. Lewy body cortical involvement may not always predict dementia in Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.
[106] Richard Camicioli,et al. Parkinson's disease is associated with hippocampal atrophy , 2003, Movement disorders : official journal of the Movement Disorder Society.
[107] J. Caviness. Myoclonus and neurodegenerative disease--what's in a name? , 2003, Parkinsonism & related disorders.
[108] D. Aarsland,et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. , 2003, Archives of neurology.
[109] Kenneth Hugdahl,et al. Neuropsychological Profile of Patients with Parkinson’s Disease without Dementia , 2003, Dementia and Geriatric Cognitive Disorders.
[110] W. Klein,et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[111] J. Caviness. Chapter 32 The clinical neurophysiology of myoclonus , 2003 .
[112] K. Marder,et al. Memory and executive function impairment predict dementia in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[113] C. Adler,et al. Small‐Amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations , 2002, Movement disorders : official journal of the Movement Disorder Society.
[114] Nancy A. Jenkins,et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[115] Yaakov Stern,et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease , 2002, Annals of neurology.
[116] D. Aarsland,et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study , 2002, Journal of neurology, neurosurgery, and psychiatry.
[117] G. Lenzi,et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease , 2002, Neurological Sciences.
[118] J. Perlmutter,et al. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. , 2002, Genomics.
[119] K. Jellinger,et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease , 2002, Journal of Neural Transmission.
[120] H. Wang,et al. Cognitive impairment in Parkinson's disease revealed by event-related potential N270 , 2002, Journal of the Neurological Sciences.
[121] C. Adler,et al. Myoclonus in Lewy body disorders. , 2002, Advances in neurology.
[122] D. Price,et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[123] Joseph E Parisi,et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. , 2002, Archives of neurology.
[124] James T Becker,et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. , 2002, Archives of neurology.
[125] J. Morris,et al. Current concepts in mild cognitive impairment. , 2001, Archives of neurology.
[126] G. Glosser. Neurobehavioral aspects of movement disorders. , 2001, Neurologic clinics.
[127] D. Aarsland,et al. Risk of dementia in Parkinson’s disease , 2001, Neurology.
[128] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[129] G. Bydder,et al. Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline , 2001, Journal of Neural Transmission.
[130] K. Marder,et al. Motor impairment in PD , 2000, Neurology.
[131] John Hardy,et al. The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.
[132] Pico Caroni,et al. Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.
[133] S. Prabhakar,et al. P300 in newly diagnosed non-dementing Parkinson's disease: effect of dopaminergic drugs. , 2000, Neurology India.
[134] G. Glosser,et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease , 2000, Neurology.
[135] H. Ross,et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease , 2000, Neurology.
[136] A. Hofman,et al. APOE and the risk of PD with or without dementia in a population-based study , 2000, Neurology.
[137] C. Adler,et al. Electrophysiological observations in hereditary parkinsonism‐dementia with Lewy body pathology , 2000, Movement disorders : official journal of the Movement Disorder Society.
[138] P. Caroni,et al. Neuropathology in mice expressing human alpha-synuclein. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[139] L. Petrucelli,et al. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[140] Yoshitaka Fuwamoto,et al. Analysis of music–brain interaction with simultaneous measurement of regional cerebral blood flow and electroencephalogram beta rhythm in human subjects , 1999, Neuroscience Letters.
[141] M. Polymeropoulos. Autosomal dominant parkinson's disease and α‐synuclein , 1998 .
[142] S. Love,et al. Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer’s disease and dementia , 1998, Journal of neurology, neurosurgery, and psychiatry.
[143] A. Flahault,et al. Neuropsychological prediction of dementia in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.
[144] D. F. Brown,et al. Neuropathologic Evidence that the Lewy Body Variant of Alzheimer Disease Represents Coexistence of Alzheimer Disease and Idiopathic Parkinson Disease , 1995, Journal of neuropathology and experimental neurology.
[145] M. Polymeropoulos. Autosomal dominant Parkinson's disease and alpha-synuclein. , 1998, Annals of neurology.
[146] G. Bernardi,et al. Age and stage dependency of P300 latency alterations in non-demented Parkinson's disease patients without therapy. , 1998, Electroencephalography and clinical neurophysiology.
[147] Hitoshi Takahashi,et al. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease , 1997, Neuroscience Letters.
[148] F. Raudino,et al. Auditory event-related potentials in Parkinson's disease. , 1997, Electromyography and clinical neurophysiology.
[149] Peter R Mouton,et al. Empirical assessment of synapse numbers in primate neocortex , 1997, Journal of Neuroscience Methods.
[150] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[151] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[152] Smiley Jf. Monoamines and acetylcholine in primate cerebral cortex: what anatomy tells us about function. , 1996 .
[153] O. Elwan,et al. Parkinson's disease, cognition and aging Clinical, neuropsychological, electrophysiological and cranial computerized tomographic assessment , 1996, Journal of the Neurological Sciences.
[154] J. Smiley. Monoamines and acetylcholine in primate cerebral cortex: what anatomy tells us about function. , 1996, Revista brasileira de biologia.
[155] M. Sliwinski,et al. Modality dependent changes in event-related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease , 1995, Journal of neural transmission. Parkinson's disease and dementia section.
[156] W. Honer,et al. Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease , 1994, Brain Research.
[157] J. Ito. Somatosensory event-related potentials (ERPs) in patients with different types of dementia , 1994, Journal of the Neurological Sciences.
[158] Dc Washington. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .
[159] Y. Parmet,et al. EEG frequency analysis in demented and nondemented parkinsonian patients. , 1994, Dementia.
[160] K. Beyreuther,et al. Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. , 1993, Dementia.
[161] M. Shindo,et al. Event-related potentials, reaction time, and cognitive state in patients with Parkinson's disease. , 1993, Advances in neurology.
[162] S. Gauthier,et al. Comparative Alterations of Nicotinic and Muscarinic Binding Sites in Alzheimer's and Parkinson's Diseases , 1992, Journal of neurochemistry.
[163] B. Oken,et al. Test-retest reliability in EEG frequency analysis. , 1991, Electroencephalography and clinical neurophysiology.
[164] N. Motomura,et al. Event‐Related Potentials in Senile Dementia of Alzheimer's Type, Multiinfarct Dementia and Parkinson's Disease , 1991, The Japanese journal of psychiatry and neurology.
[165] H. Soininen,et al. Slowing of EEG in Parkinson's disease. , 1991, Electroencephalography and clinical neurophysiology.
[166] F. L. D. Silva,et al. Basic mechanisms of cerebral rhythmic activities , 1990 .
[167] K. Kogure,et al. Cognitive impairment in Parkinson's disease assessed by visuomotor performance system and P300 potential. , 1990, The Tohoku journal of experimental medicine.
[168] T. Pedley,et al. Beta and Mu Rhythms , 1990, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.
[169] Stephen W. Scheff,et al. Quantitative assessment of cortical synaptic density in Alzheimer's disease , 1990, Neurobiology of Aging.
[170] E. Masliah,et al. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease , 1989, Neuroscience Letters.
[171] David A. Drachman,et al. Synaptic loss in Alzheimer's disease and other dementias , 1989, Neurology.
[172] R. Leiguarda,et al. Evoked potentials, reaction time and cognitive performance in on and off phases of Parkinson's disease. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[173] G. Buzsáki,et al. Nucleus basalis and thalamic control of neocortical activity in the freely moving rat , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[174] A. Korczyn,et al. EEG in demented and non‐demented parkinsonian patients , 1988, Acta neurologica Scandinavica.
[175] D. Price,et al. Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease , 1988, Neurology.
[176] D. Choi. Alzheimer's disease and dementia. , 1988, Medical Section proceedings : the ... annual Meeting of the Medical Section of the American Council of Life Insurance. American Council of Life Insurance. Medical Section. Meeting.
[177] B. Berger,et al. Major dopamine innervation of the cortical motor areas in the Cynomolgus monkey. A radioautographic study with comparative assessment of serotonergic afferents , 1986, Neuroscience Letters.
[178] M J Campbell,et al. The monoaminergic innervation of primate neocortex. , 1986, Human neurobiology.
[179] W. Ray,et al. EEG alpha activity reflects attentional demands, and beta activity reflects emotional and cognitive processes. , 1985, Science.
[180] T. Gasser,et al. Test-retest reliability of spectral parameters of the EEG. , 1985, Electroencephalography and clinical neurophysiology.
[181] C. H. Vanderwolf,et al. Cholinergic activation of the electrocorticogram: Role of the substantia innominata and effects of atropine and quinuclidinyl benzilate , 1984, Brain Research.
[182] Y. Agid,et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease , 1983, Brain Research.
[183] D L Price,et al. Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.
[184] C. H. Vanderwolf. Neocortical and hippocampal activation relation to behavior: effects of atropine, eserine, phenothiazines, and amphetamine. , 1975, Journal of comparative and physiological psychology.
[185] I. Mézan,et al. EEG findings in Parkinsonism. , 1963, Electroencephalography and clinical neurophysiology.